Real-world finerenone use in indian kidney and diabetes patients under review
NCT ID NCT06763146
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study reviews medical records of 1200 Indian adults with chronic kidney disease and type 2 diabetes who started finerenone between August 2022 and April 2024. Researchers will analyze how doctors prescribed the drug, dose changes, and lab results like kidney function and potassium levels. The goal is to understand real-world usage patterns, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
Many Locations, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Can a spice and a mindset shift ease diabetic nerve pain?